Although ALMS, the largest prospective, randomized, controlled study comparing mycophenolate mofetil to intravenous cyclophosphamide for the initial treatment of severe lupus nephritis, failed to achieve its primary end point of mycophenolate superiority, mycophenolate plus corticosteroids has become the accepted standard of care. Are we really beyond cyclophosphamide for severe lupus nephritis?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial
Clinical Rheumatology Open Access 13 November 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Ong, L. M. et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology (Carlton) 10, 504–510 (2005).
Hu, W. et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. (Engl.) 115, 705–709 (2002).
Chan, T. M. et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N. Engl. J. Med. 343, 1156–1162 (2000).
Ginzler, E. M. et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N. Engl. J. Med. 353, 2219–2228 (2005).
Chan, T. M., Tse, K. C., Tang, C. S. O., Mok, M.-Y. & Li, F. K. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 16, 1076–1084 (2005).
Moroni, G. et al. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol. Dial. Transplant. 22, 2531–2539 (2007).
Hill, G. S. et al. Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int. 59, 304–316 (2001).
Korbet, S. M., Schwartz, M. M., Evans, J. & Lewis, E. J. Severe lupus nephritis: racial differences in presentation and outcome. J. Am. Soc. Nephrol. 18, 244–254 (2007).
Mok, C. C. et al. Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am. J. Kidney Dis. 38, 256–264 (2001).
Acknowledgements
The author's work is supported in part by NIDDK grant R01 DK074661. He would also like to thank Dr. Eliza Chakravarty (Stanford) and Dr. James Tumlin (University of Tennessee) for critically reading this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Rovin, B. Lupus nephritis treatment: are we beyond cyclophosphamide?. Nat Rev Nephrol 5, 492–494 (2009). https://doi.org/10.1038/nrneph.2009.130
Issue date:
DOI: https://doi.org/10.1038/nrneph.2009.130
This article is cited by
-
Leflunomide versus cyclophosphamide in the induction treatment of proliferative lupus nephritis in Chinese patients: a randomized trial
Clinical Rheumatology (2019)
-
Guidelines for lupus nephritis—more recommendations than data?
Nature Reviews Nephrology (2012)
